1480 Eseba-vec (HB-200) plus pembrolizumab as first-line treatment of recurrent/metastatic HPV16-positive head and neck cancer: updated results in PD-L1 CPS ≥20 patients
Alan L. Ho, Lisle Nabell, Prakash Neupane, Emrullah Yilmaz, Douglas Laux, Jiaxin Niu, Marshall R. Posner, Deborah Jean Lee Wong, Yungpo Bernard Su, Jorge J. Nieva, Abdul Rafeh Naqash, Varinder Kaur, Alexander T. Pearson, Stuart J. Wong, Zujun Li, M.j. Flor, Missak Haigentz, Ari J. Rosenberg, Winston Wong, J.l. Geiger, Trisha Kaufmann, Marcos Ramirez-Marquez, Xiaoping Qing, Henning Lauterbach, Erol Wiegert, Ilian Tchakov, Mark Winderlich, David G. Pfister2024 · DOI
Recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) remains a significant clinical challenge, particularly in cases driven by Human Papillomavirus type 16 (HPV16). While immune checkpoint inhibitors like pembrolizumab have become the standard first-line (1L) treatment, the response rate for HPV16-positive patients remains modest, with only approximately 20% of patients responding to monotherapy.
Despite the presence of clear viral targets—specifically the HPV16 E6 and E7 oncoproteins—there are currently no approved therapies that specifically leverage the viral etiology of these tumors. This research evaluates a novel combination approach: using an arenavirus-based vaccine, eseba-vec (formerly HB-200), to prime the immune system against these viral antigens in tandem with pembrolizumab.
Mechanism of Action: The Arenavirus Platform
Eseba-vec utilizes a non-spreading arenavirus vector platform designed to induce a robust and highly specific CD8+ T-cell response. By delivering the genetic sequences for HPV16 E6 and E7 directly to the immune system, the vaccine aims to generate a "spark" of tumor-specific T-cells. When combined with pembrolizumab, which "releases the brakes" on the immune system by blocking the PD-1 pathway, the therapy seeks to create a synergistic effect that overcomes the immunosuppressive environment of the tumor.
Clinical Study Design and Methods
The study (NCT04180215) evaluated the safety and preliminary clinical activity of eseba-vec plus pembrolizumab as a first-line treatment. The cohort included 60 patients with HPV16-positive PD-L1+ R/M HNSCC, the majority of whom (58/60) had oropharyngeal cancer.
The treatment regimen involved:
Eseba-vec: Administered intravenously every three weeks (Q3W) for the first five doses, followed by maintenance doses every six weeks (Q6W).
Pembrolizumab: Administered at standard doses (200 mg Q3W or 400 mg Q6W).
The analysis focused specifically on a subgroup of 30 patients with a PD-L1 Combined Positive Score (CPS) of ≥20, a population known to be more responsive to immunotherapy. Within this group, 21 patients were evaluable for efficacy, having completed at least 18 weeks of follow-up and one post-baseline scan.
Safety and Tolerability
The combination demonstrated a favorable safety profile consistent with previous reports. Among the total 60-patient cohort:
Grade ≥3 treatment-emergent adverse events (TEAEs) occurred in 43.3% of patients.
Serious TEAEs were reported in 23.3% of patients.
Treatment discontinuation due to TEAEs was low, at 6.7% (4/60).
Three deaths were reported; however, two were unrelated to the study drug, and one occurred in a patient receiving additional chemotherapy as a protocol deviation.
Efficacy in the PD-L1 CPS ≥20 Population
The clinical activity in the high PD-L1 expression group (CPS ≥20) was particularly compelling. For the 21 evaluable patients:
Overall Response Rate (ORR): 52.4% per RECIST v1.1. This included 4 complete responses (one confirmed post-data cut-off), 6 partial responses, and 1 unconfirmed response.
Disease Control Rate (DCR): 85.7%.
Durability: The responses appeared durable, with 60% of confirmed responders remaining in response at the time of the data cut-off.
This ORR of 52.4% represents a substantial improvement over the historical benchmark of ~20% for pembrolizumab monotherapy in this setting, suggesting that the addition of eseba-vec significantly enhances the efficacy of checkpoint inhibition.
Conclusion and Future Directions
The updated results for eseba-vec plus pembrolizumab indicate that this combination is a promising first-line therapeutic strategy for patients with HPV16-positive R/M HNSCC, especially those with high PD-L1 expression. By specifically targeting the viral drivers of the malignancy, the arenavirus platform appears to augment the standard-of-care immunotherapy.
While progression-free survival and overall survival data are still maturing, the high response and disease control rates have prompted the initiation of AVALON-1, a Phase 2/3 randomized pivotal study. This larger trial will further define the role of this combination as a potential new standard of care for this patient population.
Summary updated
Abstract
<h3>Background</h3> Only a minority of patients (20%) with Human Papillomavirus (HPV) 16-positive recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) responds to first-line (1L) monotherapy with pembrolizumab, and no approved therapies exist targeting HPV+ disease specifically. Eseba-vec (previously known as HB-200) utilizes arenavirus vectors to induce potent HPV-16 E6 and E7-specific CD8 T-cell responses. Previously, we reported compelling clinical activity of eseba-vec alone and in combination with pembrolizumab as 1L treatment for patients with HPV16+ PD-L1 combined positive score (CPS) ≥20 R/M HNSCC. Here, we report further updated results in 1L patients with CPS ≥20. <h3>Methods</h3> Participants received intravenous eseba-vec (every 3 weeks [Q3W] for the first 5 doses, then Q6W for the sixth dose and onward) in combination with pembrolizumab (200 mg Q3W or 400 mg Q6W). Two dose levels were explored. Safety, T-cell response, and preliminary clinical activity were assessed. <h3>Results</h3> As of 5 August 2024, 60 patients with HPV16+ PD-L1+ R/M HNSCC (58 with oropharyngeal cancer) were treated with eseba-vec plus pembrolizumab in the 1L setting. Grade ≥3 treatment-emergent adverse events (TEAEs) were reported in 26/60 (43.3%) patients, serious TEAEs in 14/60 (23.3%) patients. There were 4/60 (6.7%) patients with TEAEs leading to treatment discontinuation, and 3 treatment emergent death cases (two unrelated and one related in a patient receiving additional chemotherapy as a protocol deviation). 30/60 patients exhibit PD-L1 CPS ≥20. Baseline characteristics for these 30 patients: median age 69 (range 38–76), male 26 (86.7%), White 28 (93.3%), with smoking history 15 (50%), 28 (93.3%) received prior chemoradiation and 29 (96.7%) naïve to checkpoint inhibitor (CPI). 21/30 patients are evaluable (≥1 post-baseline tumor scan) with at least 18 weeks follow-up after first dose, the overall response rate per RECIST v1.1 was 52.4% (4 complete response, one confirmed after data cut-off; 6 partial response, and 1 unconfirmed response) and disease control rate was 85.7%. 60% of the confirmed responders were ongoing at data cut-off. Progression-free survival and overall survival data are still maturing and will be presented. <h3>Conclusions</h3> Eseba-vec plus pembrolizumab continue to demonstrate an overall favorable combination safety profile and promising clinical activity in the PD-L1 CPS ≥20 population as 1L treatment in patients with HPV16+ R/M HNSCC. AVALON-1, a phase 2/3 randomized pivotal study has been initiated in this patient population. Clinical trial# NCT04180215 <h3>Trial Registration</h3> ClinicalTrials.gov NCT04180215. <h3>Ethics Approval</h3> This study was approved by Ethics and Institutional Review Boards (IRBs) at all study sites. 20-165A(5) (Memorial Sloan Kettering Cancer Center), 1282128 (University of Alabama at Birmingham Heersink School of Medicine), 1273311 (University of Kansas Medical Center), IRB22-1121 (Cleveland Clinic), 202101073 (University of Iowa), 1266389 (Banner MD Anderson Cancer Center), STUDY-19-01049 (Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute), HS-19-00931 (University of Southern California, Norris Cancer Center), ‘BUA-2023-034-001’ (University of California Los Angeles), H-200-001 (RM 662) (Stephenson Cancer Center at University of Oklahoma Health Sciences Center), 1346811 (University of Virginia Health System), IRB19-1294 (University of Chicago), PRO00036737 (Medical College of Wisconsin), i21-00729 (Grossman School of Medicine), EC/21/252/6495 ( R) (Hospital Virgen del Rocio), 1353073 (Rutgers Cancer Institute of New Jersey) All participants provided written informed consent.
BibTeX
@misc{ho2024eseba,
author = {Alan L. Ho and Lisle Nabell and Prakash Neupane and Emrullah Yilmaz and Douglas Laux and Jiaxin Niu and Marshall R. Posner and Deborah Jean Lee Wong and Yungpo Bernard Su and Jorge J. Nieva and Abdul Rafeh Naqash and Varinder Kaur and Alexander T. Pearson and Stuart J. Wong and Zujun Li and M.J. Flor and Missak Haigentz and Ari J. Rosenberg and Winston Wong and J.L. Geiger and Trisha Kaufmann and Marcos Ramirez-Marquez and Xiaoping Qing and Henning Lauterbach and Erol Wiegert and Ilian Tchakov and Mark Winderlich and David G. Pfister},
title = {{1480 Eseba-vec (HB-200) plus pembrolizumab as first-line treatment of recurrent/metastatic HPV16-positive head and neck cancer: updated results in PD-L1 CPS ≥20 patients}},
year = {2024},
doi = {10.1136/jitc-2024-sitc2024.1480},
}